Trial Profile
Phase II proof-of-concept trial of a fixed-dose combination of bacitracin/tranexamic acid (IPI-120) for wound closure in dialysis patients.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Antibacterials (Primary)
- Indications Wound infections; Wounds
- Focus Therapeutic Use
- Sponsors Harrow
- 25 Nov 2013 New trial record